LGN-20

N/A

Report date: 2025/11/17 10:50:37
NME

Base Information

Drug NameLGN-20
Drug Alias NameLGN-20CX2101ACX-2101-A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesLigand Pharmaceuticals IncChina Resources Double-Crane Pharmaceutical Co LtdSkinject Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A